80 Mile PLC a pris acte mercredi d'une annonce faite par Hydrogen Valley Ltd, dans laquelle elle détient une participation de ...
Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).
80 Mile PLC : * MISE À JOUR DU FINANCEMENT DE LA VALLÉE DE L'HYDROGÈNE * REDÉMARRAGE DE L'USINE PRÉVU DANS LES PROCHAINES SEMAINES, PRODUCTION COMPLÈTE AU ...
Long-serving Roche chief executive Severin Schwan is stepping down, to be replaced next March by Thomas Schinecker, currently head of diagnostics at the Swiss group. Schwan (pictured above ...
1 Day RHHBY 2.56% DJIA 0.77% S&P 500 1.04% Health Care/Life Sciences 0.10% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results